ATE457362T1 - Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs - Google Patents

Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs

Info

Publication number
ATE457362T1
ATE457362T1 AT05843726T AT05843726T ATE457362T1 AT E457362 T1 ATE457362 T1 AT E457362T1 AT 05843726 T AT05843726 T AT 05843726T AT 05843726 T AT05843726 T AT 05843726T AT E457362 T1 ATE457362 T1 AT E457362T1
Authority
AT
Austria
Prior art keywords
prostate cancer
urine
value
ratio
psa
Prior art date
Application number
AT05843726T
Other languages
English (en)
Inventor
Daphne Hessels
Gerald Verhaegh
Jack Schalken
Alfred Witjes
Original Assignee
Stichting Katholieke Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Katholieke Univ filed Critical Stichting Katholieke Univ
Application granted granted Critical
Publication of ATE457362T1 publication Critical patent/ATE457362T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
AT05843726T 2004-12-24 2005-12-23 Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs ATE457362T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002491067A CA2491067A1 (en) 2004-12-24 2004-12-24 Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US71955705P 2005-09-23 2005-09-23
PCT/EP2005/014021 WO2006066965A2 (en) 2004-12-24 2005-12-23 Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer

Publications (1)

Publication Number Publication Date
ATE457362T1 true ATE457362T1 (de) 2010-02-15

Family

ID=36636708

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05843726T ATE457362T1 (de) 2004-12-24 2005-12-23 Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs

Country Status (13)

Country Link
US (8) US7960109B2 (de)
EP (3) EP1761651B1 (de)
JP (1) JP4944041B2 (de)
AT (1) ATE457362T1 (de)
AU (1) AU2005318369B2 (de)
CA (2) CA2491067A1 (de)
DE (1) DE602005019294D1 (de)
DK (1) DK1761651T3 (de)
ES (2) ES2340513T3 (de)
HK (1) HK1148315A1 (de)
IL (1) IL183476A0 (de)
WO (1) WO2006066965A2 (de)
ZA (1) ZA200703746B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
WO1998045420A1 (en) 1997-04-10 1998-10-15 Diagnocure Inc. Pca3, pca3 genes, and methods of use
AU7636400A (en) 1999-09-29 2001-04-30 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
ES2363891T3 (es) 2006-03-20 2011-08-18 The Regents Of The University Of California Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
JP4943074B2 (ja) * 2006-07-03 2012-05-30 シスメックス株式会社 がん転移の判定方法及び装置
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009085196A1 (en) * 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
GB2465088C (en) * 2008-10-30 2016-01-27 Caris Mpi Inc miRNA expression in the characterisation and classification of cancer
JP2012507300A (ja) * 2008-10-30 2012-03-29 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Ｒｎａパターンを評価する方法
US7897356B2 (en) * 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
JP2010233542A (ja) * 2009-03-31 2010-10-21 Kanazawa Univ Ｒａｇｅ遺伝子の２種類のスプライシングバリアントを区別して増幅可能なプライマーセット及びプローブ
EP2320235A1 (de) 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Markerkombination zur Diagnose von Prostatakrebs
EP2320234A1 (de) 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Markerkombination zur Diagnose von Prostatakrebs
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
EP2542696B1 (de) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Theranostik-biomarker
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
CN103402767B (zh) * 2010-04-16 2016-08-03 亨特道格拉斯公司 用于制造卷帘的工序和系统
WO2012031207A2 (en) 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
CA2811744A1 (en) * 2010-10-20 2012-04-26 Universite Bordeaux Segalen Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
EP2574929A1 (de) 2011-09-28 2013-04-03 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker bei der Diagnose von Prostatakrebs
RU2668164C2 (ru) 2013-08-06 2018-09-26 Эксосам Дайэгностикс, Инк. Когорты биомаркеров мочи, профиль экспрессии генов и способы их применения
US10364469B2 (en) * 2014-01-16 2019-07-30 Illumina, Inc Gene expression panel for prognosis of prostate cancer recurrence
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
WO2016073668A1 (en) 2014-11-06 2016-05-12 The Regents Of The University Of Colorado Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
US11187710B2 (en) 2015-06-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11871895B2 (en) 2015-11-24 2024-01-16 The Johns Hopkins University Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo
US11169142B2 (en) 2016-05-11 2021-11-09 The Regents Of The University Of Colorado, A Body Corporate Viscoelastic analysis in patients with disease associated with cardiovascular system
US11913072B2 (en) * 2016-05-13 2024-02-27 Roche Molecular Systems, Inc. Detection of MET exon 14 deletions and associated therapies
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
JP7044114B2 (ja) * 2017-11-13 2022-03-30 株式会社リコー 検出判定用デバイス
WO2019169336A1 (en) * 2018-03-02 2019-09-06 The Johns Hopkins University Methods for prostate cancer detection
CN110423797A (zh) * 2019-07-11 2019-11-08 杨海涛 一种前列腺癌pca3基因双重实时pcr的引物、方法及试剂盒
CN114743593B (zh) * 2022-06-13 2023-02-24 北京橡鑫生物科技有限公司 一种基于尿液进行前列腺癌早期筛查模型的构建方法、筛查模型及试剂盒

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2422956A1 (fr) 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4690890A (en) 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
US4786600A (en) * 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4851331A (en) * 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
FR2602592B1 (fr) 1986-08-06 1989-06-30 Alain Baret Utilisation du systeme enzymatique xanthine-oxydase en immuno-analyse, procedes de dosage correspondants et coffrets de reactifs necessaires pour la mise en oeuvre de ces procedes.
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5149625A (en) * 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
US5639604A (en) 1987-09-21 1997-06-17 Gen-Probe Incorporated Homogeneous protection assay
US5283174A (en) * 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5585481A (en) * 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
US5002867A (en) * 1988-04-25 1991-03-26 Macevicz Stephen C Nucleic acid sequence determination by multiple mixed oligonucleotide probes
NL8801147A (nl) * 1988-05-02 1989-12-01 Tno Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit.
DK167254B1 (da) 1988-07-21 1993-09-27 Hartmann As Brdr Fremgangsmaade til fremstilling af formede genstande af et fluidiseret cellulosefibermateriale
US5183949A (en) * 1988-09-22 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids
US5118801A (en) * 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5219989A (en) * 1988-12-13 1993-06-15 Mcgill University Bifunctional protein for the isolation of capped mRNA
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5175383A (en) * 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5112736A (en) * 1989-06-14 1992-05-12 University Of Utah Dna sequencing using fluorescence background electroblotting membrane
US5656207A (en) 1989-06-24 1997-08-12 Gen Probe Incorporated Detecting or quantifying multiple analytes using labelling techniques
US5174986A (en) * 1989-07-05 1992-12-29 Genpharm International, Inc. Method for determining oncogenic potential of a chemical compound
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
AU662906B2 (en) 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
CA2082411A1 (en) * 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
AU2468992A (en) 1991-08-16 1993-03-16 General Hospital Corporation, The Method of gene delivery to post-mitotic cells
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
CA2125947A1 (en) * 1991-12-16 1993-06-24 Fateme Sima Sariaslani Constitutive expression of p450soy and ferredoxin-soy in streptomyces, and biotransformation of chemicals by recombinant organisms
ATE317848T1 (de) 1991-12-24 2006-03-15 Isis Pharmaceuticals Inc Unterbrochene 2'-modifizierte oligonukleotide
WO1993022461A1 (en) * 1992-05-06 1993-11-11 Gen-Probe Incorporated Nucleic acid sequence amplification method, composition and kit
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
JP4204642B2 (ja) 1992-11-05 2009-01-07 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺に特異的な膜抗原
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5773705A (en) * 1992-12-31 1998-06-30 Wisconsin Alumni Research Foundation Ubiquitin fusion protein system for protein production in plants
CA2153158A1 (en) 1993-01-07 1994-07-21 Andrew Zalewski Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
US5422252A (en) * 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5861242A (en) 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5925517A (en) * 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
KR100230718B1 (ko) 1994-03-16 1999-11-15 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 등온 가닥 변위 핵산 증폭법
AU2292495A (en) 1994-04-15 1995-11-10 Trustees Of Columbia University In The City Of New York, The Method for molecular staging of prostate cancer
WO1995032305A1 (en) 1994-05-19 1995-11-30 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
AU3889595A (en) 1994-10-05 1996-05-02 Amgen, Inc. Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
ATE340866T1 (de) * 1994-10-28 2006-10-15 Gen Probe Inc Zusammensetzungen und verfahren für die gleichzeitige detektion und quantifizierung von einer mehrheit spezifischer nuklein säure sequenzen
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
DE19513152A1 (de) * 1995-04-07 1996-10-10 Bundesrep Deutschland Verwendung eines "Immundefizienzvirus-supprimierenden Lymphokins (ISL)" zur Hemmung der Virusvermehrung, insbesondere von Retroviren
US5731148A (en) 1995-06-07 1998-03-24 Gen-Probe Incorporated Adduct protection assay
DK0912767T3 (da) 1996-07-16 2006-10-30 Gen Probe Inc Fremgangsmåde til sporing og forstærkning af nukleinsyresekvenser ved anvendelse af modificerede oligonukleotider med foröget targetspecifikt TM
US6479263B1 (en) * 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
EP1005546A2 (de) * 1997-02-25 2000-06-07 Corixa Corporation Verbindungen für die immuntherapie von prostatkrebs und verfahren zu deren verwendung
US6395278B1 (en) * 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6465611B1 (en) * 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261562B1 (en) * 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO1998045420A1 (en) 1997-04-10 1998-10-15 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6534273B2 (en) * 1997-05-02 2003-03-18 Gen-Probe Incorporated Two-step hybridization and capture of a polynucleotide
DE69836012T2 (de) 1997-05-02 2007-04-05 Gen-Probe Inc., San Diego Zwei-schritt hybridisierung und einfang von einem polynukleotid
ATE221887T1 (de) * 1997-05-08 2002-08-15 Merck Sharp & Dohme Substituierte 1,2,4-triazolo(3,4,-a)phthalazin- derivate als gaba-alpha 5-liganden
ES2260837T3 (es) * 1997-05-30 2006-11-01 Xenomics Procedimiento para detectar secuencias de acidos nucleicos en la orina.
US20020035244A1 (en) * 1997-09-09 2002-03-21 Maurice Cohen Reagents and methods useful for detecting diseases of the prostate
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
JP2002520054A (ja) 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
CA2360073C (en) * 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6528260B1 (en) * 1999-03-25 2003-03-04 Genset, S.A. Biallelic markers related to genes involved in drug metabolism
ATE466938T1 (de) 1999-03-26 2010-05-15 Jackson H M Found Military Med Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
AU7636400A (en) 1999-09-29 2001-04-30 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
AU1656501A (en) 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2303736T3 (es) 1999-12-17 2008-08-16 Bio Merieux Procedimiento para marcar un acido nucleico.
PL356908A1 (en) 2000-01-14 2004-07-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001053836A2 (en) * 2000-01-24 2001-07-26 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of prostate cancer
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
CA2403909A1 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
FR2810114B1 (fr) 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
AU2001292842A1 (en) 2000-09-19 2002-04-02 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
MXPA03003151A (es) 2000-10-13 2003-08-19 Eos Biotechnology Inc Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
AU2004209578A1 (en) * 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
CA2432365A1 (en) 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer

Also Published As

Publication number Publication date
IL183476A0 (en) 2007-09-20
WO2006066965A2 (en) 2006-06-29
CA2594125A1 (en) 2006-06-29
US9096907B2 (en) 2015-08-04
EP2325334A1 (de) 2011-05-25
CA2491067A1 (en) 2006-06-24
ZA200703746B (en) 2008-07-30
CA2594125C (en) 2016-06-14
US8257924B2 (en) 2012-09-04
US20120003640A1 (en) 2012-01-05
ES2546193T3 (es) 2015-09-21
US20160362746A1 (en) 2016-12-15
DE602005019294D1 (de) 2010-03-25
US20150307948A1 (en) 2015-10-29
DK1761651T3 (da) 2010-05-17
US10752957B2 (en) 2020-08-25
AU2005318369B2 (en) 2012-02-09
JP4944041B2 (ja) 2012-05-30
US9951390B2 (en) 2018-04-24
US20200392588A1 (en) 2020-12-17
ES2340513T3 (es) 2010-06-04
HK1148315A1 (en) 2011-09-02
EP1761651B1 (de) 2010-02-10
AU2005318369A1 (en) 2006-06-29
US20120309007A1 (en) 2012-12-06
JP2008524998A (ja) 2008-07-17
US20130261171A1 (en) 2013-10-03
EP1761651A2 (de) 2007-03-14
EP2226394A1 (de) 2010-09-08
EP2226394B1 (de) 2015-06-03
US7960109B2 (en) 2011-06-14
WO2006066965A3 (en) 2006-10-26
US20100021884A1 (en) 2010-01-28
US20180223375A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
ATE457362T1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
Sharma et al. Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools
Tilki et al. Urine markers for detection and surveillance of non–muscle-invasive bladder cancer
Turner et al. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score
Wang et al. Tumor–ratio–metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients
de Martino et al. Validation of serum C‐reactive protein (CRP) as an independent prognostic factor for disease‐free survival in patients with localised renal cell carcinoma (RCC)
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
ATE477495T1 (de) Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
EP2762574A1 (de) Nichtinvasives Diagnoseverfahren zur Diagnose von Blasenkrebs
WO2008127718A3 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
ATE548656T1 (de) Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür
Zehentner et al. Detection of α-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients
WO2006113747A3 (en) Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2007093657A2 (es) Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método
DE602006020544D1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
JP2013505429A5 (de)
Curtit et al. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay
Di Carlo et al. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors
WO2011154698A3 (en) Method,array and use thereof
Shi et al. Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles
Miyake et al. Significance of micrometastases in pelvic lymph nodes detected by real‐time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy
Fujisawa et al. Significance of micrometastases in prostate cancer
Magi-Galluzzi et al. The 17-gene genomic prostate score assay predicts outcome after radical prostatectomy independent of PTEN status
Miyai et al. Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma
Bhargava et al. Luminal B breast tumors are not HER2 positive

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1761651

Country of ref document: EP